Samuel Yamshon, MD

Samuel Yamshon, MD, is an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, as well as the medical director of the Cellular Therapy Service at NYU Langone Health in New York, New York.

Articles

Other Key Follicular Lymphoma Data From ASH 2024

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.

Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.

2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.

CD19 Expression Loss and Tafasitamab in R/R DLBCL

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.

Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.

The Phase 3 inMIND Trial: Tafasitamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.

Dissecting the Current Treatment Landscape for R/R Follicular Lymphoma

December 20th 2024

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.

Strategies to Improve CAR T-cell Durability in Lymphoma

May 15th 2024

Samuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma.